A PSMA-Targeting CD3 Bispecific Antibody Induces Antitumor Responses that Are Enhanced by 4-1BB Costimulation
- 1 May 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 8 (5), 596-608
- https://doi.org/10.1158/2326-6066.cir-19-0518
Abstract
Patients with hematological cancers have improved outcomes after treatment with bispecific antibodies that bind to CD3 on T cells and that redirect T cells towards cancer cells. However, clinical benefit against solid tumors remains to be shown. We made a bispecific antibody that targets both the common prostate tumor-specific antigen PSMA and CD3 (PMSAxCD3) and provide evidence for tumor inhibition in several preclinical solid tumor models. Mice expressing the human extracellular regions of CD3 and PSMA were generated to examine antitumor efficacy in the presence of an intact immune system and PSMA expression in normal tissues. PSMAxCD3 accumulated in PSMA-expressing tissues and tumors as detected by Immuno-PET imaging. Although PSMAxCD3 induced T-cell activation and showed antitumor efficacy in mice with low tumor burden, PSMAxCD3 lost efficacy against larger solid tumors, mirroring the difficulty of treating solid tumors in the clinic. Costimulatory receptors can enhance T-cell responses. We show here that costimulation can enhance the antitumor efficacy of PSMAxCD3. In particular, 4-1BB stimulation in combination with PSMAxCD3 enhanced T-cell activation and proliferation, boosted efficacy against larger tumors, and induced T-cell memory, leading to durable antitumor responses. The combination of CD3 bispecific antibodies and anti-4-1BB costimulation represents a therapeutic approach for the treatment of solid tumors.Keywords
Other Versions
Funding Information
- None
This publication has 39 references indexed in Scilit:
- Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate AntigensMolecular Cancer Therapeutics, 2012
- Combination Immunotherapy with 4-1BBL and CTLA-4 Blockade for the Treatment of Prostate CancerJournal of Immunology Research, 2012
- Targeting 4-1BB Costimulation to Disseminated Tumor Lesions With Bi-specific Oligonucleotide AptamersMolecular Therapy, 2011
- Effective targeting of prostate cancer by lymphocytes redirected by a PSMA × CD3 bispecific single‐chain diabodyThe Prostate, 2010
- Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletionBlood, 2009
- Therapeutic Memory T Cells Require Costimulation for Effective Clearance of a Persistent Viral InfectionJournal of Virology, 2009
- A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cellsCancer Immunology, Immunotherapy, 2007
- Comparative study of PSMA expression in the prostate of mouse, dog, monkey, and humanThe Prostate, 2006
- Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cellsMolecular Immunology, 2006
- Ligation of CD137 receptor prevents and reverses established anergy of CD8+ cytolytic T lymphocytes in vivoBlood, 2004